Vontobel Holding Ltd. Cuts Holdings in Progyny, Inc. (NASDAQ:PGNY)

Vontobel Holding Ltd. reduced its position in Progyny, Inc. (NASDAQ:PGNY) by 22.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,358 shares of the company’s stock after selling 4,860 shares during the period. Vontobel Holding Ltd.’s holdings in Progyny were worth $608,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Louisiana State Employees Retirement System purchased a new position in Progyny in the 4th quarter valued at approximately $870,000. International Assets Investment Management LLC increased its stake in Progyny by 352,414.2% in the 4th quarter. International Assets Investment Management LLC now owns 5,876,411 shares of the company’s stock valued at $218,485,000 after purchasing an additional 5,874,744 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Progyny by 2.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 35,351 shares of the company’s stock valued at $1,314,000 after purchasing an additional 883 shares in the last quarter. DekaBank Deutsche Girozentrale increased its stake in Progyny by 142.4% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 80,853 shares of the company’s stock valued at $3,042,000 after purchasing an additional 47,500 shares in the last quarter. Finally, New York State Teachers Retirement System increased its stake in Progyny by 0.6% in the 4th quarter. New York State Teachers Retirement System now owns 77,434 shares of the company’s stock valued at $2,879,000 after purchasing an additional 500 shares in the last quarter. 94.93% of the stock is owned by hedge funds and other institutional investors.

Progyny Stock Up 1.1 %

PGNY stock opened at $33.06 on Tuesday. Progyny, Inc. has a 52-week low of $29.44 and a 52-week high of $44.95. The stock’s fifty day simple moving average is $36.51 and its 200-day simple moving average is $35.68. The stock has a market capitalization of $3.18 billion, a price-to-earnings ratio of 53.32, a price-to-earnings-growth ratio of 1.35 and a beta of 1.48.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings data on Tuesday, February 27th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.04. Progyny had a return on equity of 12.64% and a net margin of 5.70%. The business had revenue of $269.94 million for the quarter, compared to analysts’ expectations of $274.08 million. During the same quarter last year, the firm earned $0.03 earnings per share. The business’s revenue was up 26.0% on a year-over-year basis. As a group, analysts anticipate that Progyny, Inc. will post 0.7 earnings per share for the current fiscal year.

Insider Activity at Progyny

In related news, Chairman David J. Schlanger sold 1,000 shares of Progyny stock in a transaction on Monday, April 1st. The stock was sold at an average price of $37.52, for a total value of $37,520.00. Following the transaction, the chairman now owns 83,631 shares in the company, valued at $3,137,835.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Chairman David J. Schlanger sold 1,000 shares of Progyny stock in a transaction on Monday, April 1st. The stock was sold at an average price of $37.52, for a total value of $37,520.00. Following the transaction, the chairman now owns 83,631 shares in the company, valued at $3,137,835.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Michael E. Sturmer sold 2,260 shares of Progyny stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $40.00, for a total value of $90,400.00. Following the completion of the transaction, the president now owns 158,532 shares in the company, valued at approximately $6,341,280. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 120,515 shares of company stock worth $4,570,131. 12.30% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $48.00 target price on shares of Progyny in a report on Wednesday, February 28th. KeyCorp lowered their target price on Progyny from $45.00 to $43.00 and set an “overweight” rating on the stock in a report on Wednesday, February 28th. SVB Leerink assumed coverage on Progyny in a report on Monday, February 26th. They set an “outperform” rating and a $49.00 target price on the stock. Truist Financial reiterated a “buy” rating and set a $46.00 target price on shares of Progyny in a report on Wednesday, April 17th. Finally, Barclays assumed coverage on Progyny in a report on Wednesday, January 3rd. They set an “overweight” rating and a $48.00 target price on the stock. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $48.30.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.